[ORGANIZATION]
Risankizumab
Featured in 2 tracked stories · first seen
Situations
[QUIET]
[BUSINESS]
AbbVie IBD treatment clinical efficacy data
2 clusters · 5 sources · last updated
Latest: AbbVie reports clinical remission data for IBD treatments
AbbVie has presented new clinical data regarding the efficacy of its inflammatory bowel disease (IBD) treatments, specifically risankizumab (SKYRIZI) and upadacitinib (RINVOQ), for patients with Crohn’s disease and ulcer
Also covered in
-
FDA approves subcutaneous Skyrizi induction for Crohn’s disease
[HEALTH] · 7 sources ·